Join

Compare · CWBR vs LMDX

CWBR vs LMDX

Side-by-side comparison of CohBar Inc. (CWBR) and LumiraDx Limited (LMDX): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both CWBR and LMDX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
  • LMDX is the larger of the two at $2.23B, about 81.0x CWBR ($27.6M).
  • LMDX has more recent analyst coverage (4 ratings vs 1 for CWBR).
MetricCWBRLMDX
Company
CohBar Inc.
LumiraDx Limited
Price
$0.95+7.66%
$0.02-53.80%
Market cap
$27.6M
$2.23B
1M return
-
-
1Y return
-
-
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Exchange
NASDAQ
NASDAQ
IPO
News (4w)
0
0
Recent ratings
1
4
CWBR

CohBar Inc.

CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes mellitus, acute respiratory distress syndrome, cancer, atherosclerosis, cardiovascular, and neurodegenerative diseases, such as Alzheimer's disease. Its lead MBT candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial-derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases, CB5064 analogs for COVID-19 associated ARDS, MBT5 analogs for CXCR4-related cancer and orphan diseases, and MBT3 analogs for cancer immunotherapy. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.

Latest CWBR

Latest LMDX